Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s share price fell 3.3% during trading on Friday . The stock traded as low as $11.77 and last traded at $12.17, with a volume of 134,172 shares changing hands. The stock had previously closed at $12.59.

Several research firms recently commented on SYRS. HC Wainwright began coverage on Syros Pharmaceuticals in a research note on Monday, July 18th. They issued a “neutral” rating and a $10.00 target price for the company. Cowen and Company began coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating for the company. JMP Securities began coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $22.00 target price for the company. Wedbush began coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $18.00 target price for the company. Finally, Piper Jaffray Cos. began coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “overweight” rating and a $20.00 target price for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Syros Pharmaceuticals currently has an average rating of “Buy” and an average target price of $17.50.

The stock’s market capitalization is $284.46 million. The company has a 50 day moving average of $11.46 and a 200 day moving average of $12.67.

In other news, Director Robert Nelsen purchased 400,000 shares of the stock in a transaction dated Wednesday, July 6th. The shares were bought at an average cost of $12.50 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Redmile Group, Llc purchased 432,746 shares of the stock in a transaction dated Wednesday, July 6th. The shares were purchased at an average price of $12.50 per share, for a total transaction of $5,409,325.00. The disclosure for this purchase can be found here.

Several institutional investors have recently modified their holdings of SYRS. Weiss Multi Strategy Advisers LLC purchased a new position in shares of Syros Pharmaceuticals during the second quarter valued at about $832,000. Redmile Group LLC bought a new stake in Syros Pharmaceuticals during the second quarter valued at $15,058,000. Aisling Capital LLC bought a new stake in Syros Pharmaceuticals during the second quarter valued at $16,490,000. Deerfield Management Co. bought a new stake in Syros Pharmaceuticals during the second quarter valued at $38,028,000. Finally, Flagship Ventures Fund IV General Partner LLC bought a new stake in Syros Pharmaceuticals during the second quarter valued at $87,241,000.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.